Izotropic ( (TSE:IZO) ) has provided an update.
Izotropic Corporation has completed a pre-submission meeting with the FDA regarding its IzoView Breast CT Imaging System, focusing on its use for breast cancer screening. The meeting facilitated a collaborative exchange, addressing key topics such as clinical study protocol, benefits versus risks of contrast-enhancement, and the management of breast cancers detected by IzoView but not visible on other imaging methods. The discussions are expected to advance the regulatory strategy for the IzoView system, potentially enhancing the company’s positioning in the breast cancer imaging market.
More about Izotropic
Izotropic Corporation is a medical device company that specializes in commercializing imaging-based products. These products utilize innovative and emerging technologies aimed at improving the accuracy of screening, diagnosing, and treating breast cancers.
YTD Price Performance: 404.00%
Average Trading Volume: 50,942
Technical Sentiment Signal: Sell
Current Market Cap: $15.87M
Learn more about IZO stock on TipRanks’ Stock Analysis page.